ReviewPharmaceutical research2017
Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration.
Review in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 1 synthesis or guideline pooled it, 244 citations in OpenAlex.
- Bone Morphogenic Protein for Upper Extremity Fractures: A Systematic Review.Hand (New York, N.Y.) · 2023Pooled it
- Engineering high-fidelity bone organoids: Operational classification, multilineage crosstalk, biofabrication evidence, and translational validation.Materials today. Bio · 2026Article
- Hydrogel-Based BMP-2 Delivery for Bone Regeneration: From Material Control to Biological and Translational Evaluation.Polymers · 2026Review
- Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022.Global spine journal · 2026Article
- A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.Current osteoporosis reports · 2026Review
- Sustained release PLGA microspheres loaded with a bone-affinity Bmp2 enhance fracture healing and mitigate heterotopic ossification.Bioactive materials · 2026Article
- Anti-miR-195-engineered mesenchymal stem cells promote migration, vascularization, and ECM protein expression in vivo.Stem cell research & therapy · 2026Article
- Dose-Dependent Osteoinduction by rhBMP-2-Loaded β-Tricalcium Phosphate Scaffolds in Rabbit Critical-Sized Calvarial Defects: Histological, Histomorphometric, CD31 Immunohistochemical Evaluation.International journal of molecular sciences · 2026Article
- Mussel-inspired adhesive hydrogel reprograms osteoimmune niche for robust bone regeneration in complex defects.Materials today. Bio · 2026Article
- Multiple Drug Delivery Ability of Calcium Phosphate Scaffolds promotes Osteogenic Gene Expression in In Vitro Co‑culture Model.Regenerative engineering and translational medicine · 2026Article
- The Osteoimmunologic Basis of Biologic and Bioengineered Scaffolds in Fracture Healing.Bioengineering (Basel, Switzerland) · 2026Review
- Development of a growth factor bioavailability enhanced allograft (GFBA) for bone regeneration.Cell and tissue banking · 2026Article
- Bone Induction as a Function of Size and Chemical Composition of Calcium Phosphate Granules in Osteogrow-C Evaluated in Animal Models: A 1-Year Follow-Up.Biomaterials research · 2026Article
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Advanced biomaterial-based approaches for medication-related osteonecrosis of the jaw.Open life sciences · 2026Article
- Synergistic Advances in Additive Manufacturing and Surface Engineering for Polymeric Biomedical Devices.ACS polymers Au · 2025Review
- Fabrication and Evaluation of Thermoresponsive GPNMB-Hydrogels as an Innovative Osteogenic Therapeutic Strategy.Pharmaceutical research · 2025Article
- Anionic Citrate-Based 3D-Printed Scaffolds for Tunable and Sustained Orthobiologic Delivery to Enhance Tissue Regeneration.Advanced functional materials · 2025Article
- Modern Approaches and Emerging Biological Therapies to Treat Fracture Nonunion.Pharmaceutics · 2025Review
- Low-Dose Bone Morphogenetic Protein Use in Spinal Fusion : Rethinking Clinical Efficacy.Journal of Korean Neurosurgical Society · 2025Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone morphogenetic proteins (BMPs) are responsible for bone formation during embryogenesis and bone regeneration and remodeling. The osteoinductive action of BMPs, especially BMP-2 and BMP-7, has led to their use in a range of insurmountable treatments where intervention is required for effective bone regeneration. Introduction of BMP products to the market, however, was not without reports of multiple complications and side effects. Aiming for optimization of the therapeutic efficacy and safety, efforts have been focused on improving the delivery of BMPs to lower the administered dose, localize the protein, and prolong its retention time at the site of action. A major challenge with these efforts is that the protein stability should be maintained. With this review we attempt to shed light on how the stability of BMPs can be affected in the formulation and delivery processes. We first provide a short overview of the current standing of the complications experienced with BMP products. We then discuss the different delivery parameters studied in association with BMPs, and their influence on the efficacy and safety of BMP treatments. In particular, the literature addressing the stability of BMPs and their possible interactions with components of the delivery system as well as their sensitivity to conditions of the formulation process is reviewed. In summary, recent developments in the fields of bioengineering and biopharmaceuticals suggest that a good understanding of the relationship between the formulation/delivery conditions and the stability of growth factors such as BMPs is a prerequisite for a safe and effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.